DYN - Dyne Therapeutics Inc logo

Dyne Therapeutics Inc

DYN
Rev —top 1%5Y
Compare DYN Hold

Dyne Therapeutics develops therapeutics for genetically driven neuromuscular diseases, focusing on conditions like myotonic dystrophy and Duchenne muscular dystrophy. Its FORCE platform aims to deliver disease-modifying treatments targeting muscle and CNS.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$946today

Score Overview

1 Year
Score—
Net Growth-16.40%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score—
Net Growth-247.92%
Net TrendNever
Net Income Consistency—
Rev Growth—
Rev TrendNever
Revenue Consistency—
All Time
Score—
Net Growth-6x
Net TrendNever
Net Income Consistency
Rev Growth—
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Dyne Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. DYN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-02
$ 15.20—
1 Year2025-10-02
$ 12.5521.12%
5 Years2021-10-01
$ 16.07-5.41%
All Time2020-09-17
$ 23.90-36.40%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 519M$ 898M
2025$ 0.00-$ 446M$ 1.11B
2024$ 0.00-$ 317M$ 642M
2023$ 0.00-$ 235M$ 123M
2022$ 0.00-$ 165M$ 256M
2021$ 0.00-$ 149M$ 376M
IPO2020$ 0.00-$ 58M$ 345M
DYN - Dyne Therapeutics Inc logo

Dyne Therapeutics Inc fundamental performance

Across Dyne Therapeutics Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 58M to -$ 446M. Revenue increased in 0% of the years measured; net income in 0%.

Membership

Explore DYN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies